AbbVie
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Illinois, United States · 10K+ Employees
View Company Info for Free
Overview
Headquarters
1 N Waukegan Rd, North Chicago, Illinois...Phone Number
(847) 932-7900Website
www.abbvie.comRevenue
$62.8 BillionStock Symbol
ABBVIndustry
ZI Rank: 5
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
47
48
2
5
4
5
About AbbVie
AbbVie Inc. is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and health solutions that address some of the worlds most complex medical challenges. Headquartered in North Chicago, Illinois, the company operates internationally and focuses on advancing treatments that improve patient outcomes and overall quality of life. AbbVies scientific and commercial efforts are concentrated in several core therapeutic areas, including immunology, oncology, neuroscience, eye care, and medical aesthetics, along with other specialty areas where significant unmet medical needs exist. Through these focus areas, the company works to create therapies that help patients manage chronic, serious, and often life-altering diseases.Explore more
AbbVie Org Chart
MB
Chief Revenue Officer, Transition Lead & Cons...
AY
Commercial
MI
Commercial
NB
Commercial
FB
Commercial
BH
Commercial
AB
Commercial
SD
Commercial
AM
Commercial
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AbbVie your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
AbbVie, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when AbbVie launches new products
Congratulate Masked Content for being promoted to Masked Content at AbbVie
Earning: See what the market has to say on AbbVie recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if AbbVie is spiking on competitors!
Check if AbbVie has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if AbbVie had a recent Job posting/layoffs
Funding: Get notified immidiatlly once AbbVie has new funding data
Recommended Actions
Find VP level buyers at AbbVie
Find 3 more new buyers
Compare Similar Companies to AbbVie
Compare insights from companies similar to AbbVie, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
AbbVie
$62.8B
10K+
Public
-
2013
CL
Carrianne LudwigDirector of Chief Revenue Officer and Vendor Partnerships, Oncology Early Development
$37.2B
10K+
Public
$2B
1980
CC
Carlos ColladoChief Financial Officer, Country & LATAM Distributors (Mexico)
Company Profile Activity
Activity Insights
AbbVie is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AbbVie is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AbbVie.
AbbVie Tech Stack
A closer look at the technologies used by AbbVie
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
AbbVie News & Media
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
NORTH CHICAGO, Ill., June 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden. Final results from the Phase 3...Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
AbbVie (NYSE:ABBV) at $224.95 sits at the center of a sharp bull-bear debate. The pharma giant has climbed 53.59% since the start of 2024 off its 2024 lows, but a balance sheet carrying negative shareholders’ equity of -$6.6 billion complicates conviction at this price. AbbVie is the immunology heavyweight behind Skyrizi, Rinvoq, and legacy Humira, ... Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225Is AbbVie Inc. (ABBV) A Good Stock To Buy Now?
Is ABBV a good stock to buy? We came across a bullish thesis on AbbVie Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $225.42 as of June 9th. ABBV’s trailing and forward P/E were 110.50 and 15.82 respectively according to Yahoo Finance. AbbVie […]FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means
The agency’s letter cited manufacturing-related items and raised no safety or efficacy concerns. Werschler, a Spokane dermatologist who has served as a clinical trial investigator in dermatology and aesthetic medicine, explains how a Complete Response Letter functions and what a serotype E toxin could add to the category.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AbbVie
Sign Up For FreeTo access detailed company insights
AbbVie Inc. is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and health solutions that address some of the worlds most complex medical challenges. Headquartered in North Chicago, Illinois, the company operates internationally and focuses on advancing treatments that improve patient outc... Read More
